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ABSTRACT 
The ARTemis Trial tested standard neoadjuvant chemotherapy ± Bevacizumab  in the 
treatment of HER2 negative early breast cancer. We compare data from central 
pathology review with report-review and also the reporting behaviour of the two central 
pathologists. 
800 women with HER2-negative early invasive breast cancer were recruited. 
Response to chemotherapy was assessed from local pathology reports for 
pathological complete response in breast and axillary lymph nodes. Sections from the 
original core biopsy and surgical excision were centrally reviewed by one of two trial 
pathologists blinded to the local pathology reports. Pathologists recorded response to 
chemotherapy descriptively and also calculated residual cancer burden. 10% of cases 
were double-reported to compare the central pathologists’ reporting behaviour. 
 
Full sample retrieval was obtained for 681 of the 781 patients (87%) who underwent 
surgery within the trial and were evaluable for pathological complete response. 483 
(71%) were assessed by JT, and 198 (29%) were assessed by EP. Residual cancer 
burden calculations were possible in 587/681 (86%) of the centrally reviewed patients, 
since 94/681 (14%) had positive sentinel nodes removed before neoadjuvant 
chemotherapy invalidating residual cancer burden scoring. Good concordance was 
found between the two pathologists for residual cancer burden classes within the 65-
patient quality assurance exercise (kappa 0.63 (95%CI 0.57-0.69)). Similar results 
were obtained for the between-treatment arm comparison both from the report-review 
and the central pathology review. For pathological complete response, report-review 
was as good as central pathology review but for minimal residual disease, report-
review overestimated the extent of residual disease.  
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In the ARTemis Trial central pathology review added little in the determination of 
pathological complete response but had a role in evaluating low levels of residual 
disease. Calculation of residual cancer burden was a simple and reproducible method 
of quantifying response to neoadjuvant chemotherapy as demonstrated by 
performance comparison of the two pathologists.  
 
Funding: Cancer Research UK (CRUK/08/037), Roche, Sanofi -Aventis. 
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The ARTemis trial is an open-label, randomised, phase 3 trial assessing the efficacy 
of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, 
and cyclophosphamide, for women with HER2-negative early breast cancer. Its 
primary endpoint was pathological complete response, defined as the absence of 
invasive disease in the breast and axillary lymph nodes. Initially, the two randomised 
arms of the trial were compared in terms of rates of pathological complete response 
as determined by a two-reader blinded review of local pathology reports by the Chief 
Investigators.1  In addition a central pathology review and a large-scale two-stage 
pathology quality assurance exercise was undertaken. Thereby the accuracy of this 
commonly used primary endpoint in neoadjuvant chemotherapy breast cancer trials 
was assessed and compared with the two-reader report-review which until now has 
been the standard used by this group. 2  In addition the reliability of central specimen 
review has been investigated by independent double-reading of residual cancer 
burden categories carried out by the two central pathologists in a subset of cases. This 
allows us to report on the comparison between assessment of local pathology 
reporting and central pathology review of original diagnostic material and also the 
reporting behaviour of the two reviewing pathologists. Although central pathological 
review has been carried out in studies reporting major centre results 3 as far as the 
authors are aware this is the first report of central pathology review of pathological 
complete response with residual cancer burden scoring and class definition, carried 
out as part of a multi-centre large randomised phase 3 trial. 
 
PATIENTS AND TREATMENTS 
Between May 2009 and January 2013, the ARTemis trial recruited 800 women ≥18 
years old with newly diagnosed HER2-negative early invasive breast cancer 
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(radiological tumour size >20 mm, with or without axillary involvement). Patients with 
inflammatory cancer, T4 tumours with direct extension to the chest wall or skin, and 
ipsilateral supraclavicular lymph node involvement were also eligible with any size of 
primary tumour. Full eligibility criteria details have been described in detail elsewhere.1  
Patients were randomised from 66 UK sites and assigned, via a central computerised 
minimisation procedure, to three cycles of docetaxel (100 mg/m² once every 21 days) 
followed by three cycles of fluorouracil (500 mg/m²), epirubicin (100 mg/m²), and 
cyclophosphamide (500 mg/m²) once every 21 days (docetaxel-
fluorouracil/epirubicin/cyclophosphamide), without or with four cycles of bevacizumab 
(15 mg/kg) (Bevacizumab+docetaxel-fluorouracil/epirubicin/cyclophosphamide). 781 
patients (98% of the randomised 800) underwent surgery following their neo-adjuvant 
treatment and could be assessed, via local pathology reports, for the primary endpoint 
of absence of invasive breast cancer in the breast and axillary lymph nodes. 
 
METHODS 
Diagnostic and surgical excision histopathology slides were requested from the 
relevant participating sites for all of the 781 evaluable patients. All retrieved cases 
underwent central independent review, blinded to the local histopathology report, 
including any block descriptions, by an experienced breast histopathologist with a 
special interest in neoadjuvant clinical trials (JT & EP) between June 2011 and March 
2016. The reviewing pathologist was not the same as the pathologist who had 
previously assessed the slides locally, and/or would have access to the histopathology 
results at their hospital. Any missing slides or additional relevant operations (e.g. 
sentinel lymph node biopsy) were re-requested as necessary. The variables recorded 
were maximum invasive tumour size in two dimensions, whole tumour size (including 
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ductal carcinoma in situ) in two dimensions, post treatment tumour grade, presence of 
lymphovascular invasion, presence and nature of in situ disease, percentage tumour 
cellularity, percentage cellularity that is in situ disease, total number of lymph nodes, 
number of positive lymph nodes and size of largest nodal metastasis.  
 
As well as assessing the validity of the findings from the blinded review of local 
pathology reports, an inter-pathologist reproducibility exercise was also undertaken. 
For this, a randomly chosen 10% of patients had samples reviewed by both 
pathologists for determination of levels of agreement between central review findings. 
To simplify this exercise variables were restricted to those required to calculate the 
residual cancer burden score: invasive size (length and width), percent tumour 
cellularity, percent of tumour that is DCIS, size of largest nodal metastasis and number 
of positive nodes.4 The 10% sample was randomly chosen, whilst ensuring a 
representative residual cancer burden class split, as recorded by the first pathologist’s 
reviews. This approach was written into the pre-planned agreement decided by the 
ARTemis Trial Management Group. 10% of ARTemis cases for co-review was the 
opportunistic sample that was deemed a manageable workload for the two ARTemis 
pathologists. 
 
The results of the central pathology review were also compared with the outcome 
results as determined by the central review of the original histopathology reports from 
the source laboratory. In particular, we compared rates of pathological complete 
response and minimal residual disease as determined by formal assessment of the 
residual cancer burden and by interpretation of the histopathology. Original pathology 
reports were reviewed by the two Chief Investigators (LH & HME) according to residual 
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cancer burden class definitions laid out in the Trial Protocol. The primary end-point of 
the trial was pathological complete response and that was the main focus of report-
review by the Chief Investigators. Detailed information in the pathology report was not 
always available to enable estimates of degrees of partial response by the Chief 
Investigators who were given guidance by the Trial Pathologists as follows: 
pathological complete response – No residual invasive carcinoma in the breast or 
lymph nodes; residual cancer burden1/minimal residual disease – residual tumour 
<5mm; residual cancer burden 2 - < 50% tumour cellularity; residual cancer burden 3 
– no appreciable response. The local pathologists were not given any formal reporting 
guidelines specifically for this trial. 
 
STATISTICAL METHODS 
Agreement between the two pathologists’ residual cancer burden classes, and also 
between central review and local reports in determination of pathological complete 
response, was undertaken using the kappa statistic. Agreement between the two 
pathologists in terms of residual cancer burden scores and its six components were 
scrutinised using Bland-Altman plots and assessed using overall concordance 
correlation coefficient. 5 Comparison of patient characteristics between groups was 
undertaken using chi-squared tests with continuity correction where appropriate. 
Logistic regression was used to assess the effect of randomised treatment arm on 
pathological complete response rates, after adjustment for stratification factors. 
 
RESULTS 
A total of 22,916 slides from 727 patients were reviewed. Full sample retrieval was 
obtained for 681 (87%) of the 781 ARTemis patients who underwent surgery within 
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the trial and were evaluable for the primary endpoint of pathological complete 
response. 483/681 patients (71%) were assessed by JT, and 198/681 patients (29%) 
by EP. The maximum number of slides per patient was 164; median 29 slides.  94/681 
patients (14%) had a positive pre-chemotherapy sentinel lymph node biopsy (SLNB) 
thus invalidating the calculation of a residual cancer burden score at surgery. Residual 
cancer burden scores and classes were thus calculated on the remaining 587 patients 
(75% of the 781). Patient characteristics of the 587 patients with assessable residual 
cancer burden appeared representative of the trial sample as a whole (Table 1). 
 
INTER-RATER REPRODUCIBILITY OF PATHOLOGISTS 
65 patients were double reviewed by JT and EP. The 65 patients were representative 
of the 587 sample as a whole in terms of patient characteristics (Table 1) and the 
random sampling technique determined that they were also representative in terms of 
residual cancer burden class as recorded by the first pathologist’s central review. 
 
Residual Cancer Burden Class 
The two pathologists showed very similar reporting profiles for residual cancer burden 
class (observed frequencies of residual cancer burden 0:1:2:3 being 14:9:32:10 for 
pathologist 1 and 13:9:34:9 for pathologist 2) (Table 2). In 52/65 (80%) of patients 
there was agreement on residual cancer burden class, and in 13/65 (20%) where there 
was disagreement none were more than by one residual cancer burden class. A good 
level of agreement was observed over all residual cancer burden classes (Kappa 0.70 
(95%CI 0.55-0.84)) (Figure 1). No differences were found between patient groups 
where JT and EP agreed on residual cancer burden class (n=52) or disagreed (n=13), 
in terms of randomised treatment arm or stratification variables (age, ER status, 
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tumour size, clinical involvement of axillary nodes, locally advanced/inflammatory 
disease data not shown). 
 
Residual Cancer Burden Score 
For the 13 patients where there was disagreement in residual cancer burden class, 
the majority of disagreements were due to the two pathologists’ residual cancer burden 
scores falling just either side of the published residual cancer burden score cut-points 
of 1.36 and 3.28 (Figure 2). There was good overall concordance in residual cancer 
burden score (concordance correlation coefficient 0.75 (95%CI 0.40-0.91)), with the 
average discrepancy in residual cancer burden score being of the magnitude 0.245 
(IQR 0.135-0.501, range 0.085-1.840).  
 
Components of the Residual Cancer Burden Score 
Focusing on the 13 patients where the two pathologists differed in residual cancer 
burden class assignment, the greatest inter-rater variability was in the assessment of 
percentage of ductal carcinoma in situ within the tumour (concordance correlation 
coefficient -0.04 (95%CI -0.30-0.21)) and, to a lesser extent, in the assessment of 
invasive size [concordance correlation coefficient 0.20 (95%CI -0.12–0.47) for width 
and concordance correlation coefficient 0.35 (95%CI -0.11-0.68) for length] and 
percent of tumour cellularity (concordance correlation coefficient 0.30 (95%CI -0.05-
0.59)). The strongest agreement was observed in identification of number of positive 
nodes (concordance correlation coefficient 0.95 (95%CI 0.85-0.98)) followed by size 
of the largest nodal metastasis (concordance correlation coefficient 0.74 (95%CI 0.37-
0.91)).  
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Sources of discrepancy 
Seven cases where there was a disagreement in residual cancer burden class due to 
substantial differences in size measurement, cellularity or nodal status were reviewed 
again with joint discussion by the two pathologists. Sources of discrepancy included 
interpretation of multiple tumour foci as one lesion or multiple lesions, measurement 
of lesion size from single slides or estimating total number of slides, inclusion of pre-
treatment sentinel lymph node metastases in the residual cancer burden calculation, 
errors in measurement, and interpretation of degenerate cells in post treatment lymph 
nodes as metastasis or not. The different weightings of the elements of the residual 
cancer burden equation reduce the effect of the variance among those component 
scores. 
 
CENTRAL REVIEW OF PATHOLOGY SPECIMENS VS REVIEW OF LOCAL 
PATHOLOGY REPORTS: INTER-METHOD RELIABILITY 
Both methods determined similar levels of pathological complete response in the 587 
patients where both assessment results were available; 121 (21%) with residual 
cancer burden class 0 from central pathology review and 119 (20%) reported as 
pathological complete response from local pathology report (Table 3). A good level of 
agreement was observed between the two methods’ findings when grouped as the 3 
levels of residual cancer burden 0 (pathological complete response) vs residual cancer 
burden 1 (minimal residual disease) vs residual cancer burden 2/3 
(Moderate/extensive disease) (kappa 0.63 (95%CI 0.57-0.69) (Figure 3). However, for 
6 patients, the level of disagreement was by more than one class (1 patient with 
pathological complete response from the report-review but residual cancer burden 
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class 2 from specimen review, and 5 patients with Moderate/extensive disease from 
the report-review but with residual cancer burden class 0 from the specimen review.) 
 
Slides for 5 of the 6 cases were available for second review by one of the pathologists 
(EP). Sources of discrepancy included not receiving all the tumour slides for review (2 
cases) and interpretation of residual tumour as ductal carcinoma in situ or invasive 
disease (1 case). In one case, the second review agreed with the histopathology report 
(residual tumour) rather than the central review (pathological complete response). In 
another case called pathological complete response on central review, the 
discrepancy appears to be due to inconsistency in the original report in calling tumour 
cells in the node viable and non-viable; both central reviewers thought this represented 
an area of necrosis. 
 
 
ARTemis PRIMARY ENDPOINT RESULTS 
The ARTemis trial’s primary endpoint was previously reported using the local 
pathology report-reviews on 781 patients and showed significantly more 
Bevacizumab+docetaxel-fluorouracil/epirubicin/cyclophosphamide patients achieving 
a pathological complete response compared with docetaxel-
fluorouracil/epirubicin/cyclophosphamide patients: 22% (95%CI 18–27) of 388 
Bevacizumab+docetaxel-fluorouracil/epirubicin/cyclophosphamide patients compared 
with 17% (95%CI 13–21) of 393 docetaxel-fluorouracil/epirubicin/cyclophosphamide 
patients (adjusted p=0.03) (Table 4A).1  Using the residual cancer burden classes 
from the central pathology specimen review the results remained the same: 25% 
(95%CI 20–30) of 290 Bevacizumab+docetaxel-
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fluorouracil/epirubicin/cyclophosphamide patients achieved a residual cancer burden 
0 compared with 16% (95%CI 12–21) of 297 docetaxel-
fluorouracil/epirubicin/cyclophosphamide patients (adjusted p=0.02) (Table 4B). 
 
Likewise previously, using local pathology report-reviews, pathological complete 
response rates had been found to differ significantly across both ER status (ER 
negative 38% [95% CI 32–45], weakly positive 41% [29–53], strongly positive 7% [5–
9]; p<0.0001), and tumour grade (grade 1/2 7% [4–11], grade 3 29% [25–34]; 
p<0.0001). Using the central pathology specimen review, similar results were found 
for rates of residual cancer burden 0; ER negative 39% [95% CI 32–46], weakly 
positive 35% [23–48], strongly positive 7% [5–11] (p<0.0001) and grade 1/2 7% [4–
12], grade 3 31% [26–37] (p<0.0001).   
 
DISCUSSION 
This review focused on the presence or absence of pathological complete response 
in the excision specimen including the presence of residual ductal carcinoma in situ. 
Local pathologists were not given reporting proformas or guidelines for assessment of 
response which have been shown to aid concordance between pathologists in clinical 
trials. 6 Because the reviewing pathologists were assessing the original sections in the 
overwhelming majority of cases analytical issues do not impinge on this central review 
although differences in practice among different local laboratories would necessitate 
caution in drawing any comparison between centres. 
 
In this review the pathologists were blinded to the macroscopic description and 
therefore had to reconstruct the tumour bed dimensions from the slides as best they 
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could.  With hindsight given the differences in reporting practice in this area access to 
reports would have been of benefit in some cases but not in others. Normally a 
pathologist records a block map to aid reconstruction of the tumour area when viewing 
the slides, and this was highlighted as being of particular importance for accurate 
assessment of response in the recent BIG-NABCG working group recommendations.7  
In some cases the tumour bed was present on megaslides and this made assessment 
much easier. The assessment of tumour bed size is often not straightforward following 
neoadjuvant chemotherapy because the tumour is poorly defined macroscopically, 
and it can be difficult to determine the tumour boundaries histologically. Tumour 
cellularity can be very heterogeneous, and is also difficult to assess in spite of the 
availability of online guidance tools 7  8 and there is inconsistency amongst 
pathologists in these assessments.9   Agreement about pathological complete 
response should however be good and will only usually cause difficulty if small 
residues of tumour cells are overlooked, or if there is difficulty in interpreting in situ 
from invasive disease. Although in this study the best level of agreement in the 
reviewing pathologists’ cross-over study was of numbers of lymph nodes this also is 
not always easy to determine without the macroscopic description. In some cases the 
local pathologist had written on the slide to state the number of nodes present. Our 
data are similar to those recorded in a recent audit where a residual cancer burden 
score concordance of 0.25 points was reported for most cases with a kappa value of 
0.714 between residual cancer burden classes. In this study the reviewing pathologist 
had access to a block map/description. 10  The concordance between the two 
pathologists is better than recorded in a recent review of consistency of reporting of 
residual cancer burden and replicates the finding that the reporting of the lymph node 
component of the score is more reproducible.9 Given the limitations of this study 
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detailed above with lack of access to source reports and block descriptions, the 
residual cancer burden is shown to be a very robust system for quantifying residual 
disease in the clinical trial context. 
 
The central pathology review was immensely labour-intensive. The maximum number 
of slides submitted for a single case was 164 (median 29 per case). At best it was only 
possible to review three or four cases per hour. Not only was it time-consuming for the 
pathologists but it also placed a burden on local pathology departments retrieving 
slides and a considerable logistic burden for the Trials Office. One must question 
whether the exercise was worth the effort given that there was no clinically significant 
numerical change in the end results. However, one cannot generalise about central 
pathology review. In some trials central review is used at the outset to confirm eligibility 
whether this be Her-2 or ER status for example or a particular tumour type e.g. triple 
negative breast cancer. In the ALTTO Trial both Her-2 and ER status were changed 
following central re-testing in 5 – 15% of cases.11  An important distinction must be 
drawn here between re-testing, potentially using different reagents and conditions, and 
the review of original diagnostic material. In ARTemis we accepted a patient’s eligibility 
as reported but reviewed critically the endpoint which was very specifically 
pathological. 
 
Review of pathology reports by the two Chief Investigators was made more difficult by 
a lack of standardisation of how local reports were written – not all units use easy-to-
read synoptic reports. Moreover the majority of standardised reports are designed for 
the adjuvant setting without specific fields for the additional variables that need to be 
recorded post neoadjuvant therapy, such as tumour cellularity and fibrosis in lymph 
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nodes. We accept that review of lesser degrees of tumour response to neoadjuvant 
chemotherapy by report-review was imperfect particularly for residual cancer burden 
class 2 (an intermediate level of response) and this is reflected by our concordance 
data. However the primary endpoint of this clinical trial was pathological complete 
response and we have shown that this is reported reliably by local pathologists. 
Standardisation of routine reporting in clinical practice for neoadjuvant cases has been 
addressed recently by an international working group which should make this easier 
when designing future clinical trials.12 It is possible that should such standardisation 
be adopted, a measure of response such as residual cancer burden could be 
calculated locally. Also, although there is some evidence that pathologists are better 
at assessing chemotherapy response by reading pathology reports than are practicing 
clinicians13 this was not borne out by our data.  It was evident on review of some of 
the cases where there were discrepancies between report-review and central review 
that this was due to missing slides. In this trial the two pathologists were involved in 
the resolution of disputed minimal residual disease on report-review and were 
probably helpful in that area but minimal residual disease was not an end point of the 
trial. Furthermore one must urge caution in trying to make direct comparisons between 
residual cancer burden and more descriptive approaches to assessment of response 
to neoadjuvant chemotherapy particularly in equating residual cancer burden with 
minimal residual disease. Residual cancer burden 1 is strongly dependent on low 
tumour cellularity while minimal residual disease as determined by the report review, 
where there was often no information on comparison of pre and post treatment tumour 
cellularity, was heavily influenced by residual tumour size and these are not always 
the same. 
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The literature on central pathology review of clinical trials is limited. The NSABP 
requires central pathology review for its randomised clinical trials and central reviewers 
are trained to operate with 90% concordance on pathological features compared with 
65% concordance between local and central reporting in the NSABP B-18 trial for 
example. 14 Recently reported central review of bone marrow fibrosis showed a 
concordance of 58% between central and local reporting whereas a central panel of 
three reviewing pathologists achieved consistency of 88% for all three pathologists 
and 98% for two.15 However we were unable to find any reports of central pathology 
review in the context of neoadjuvant breast cancer trials. 
 
We chose residual cancer burden as our method of measuring chemotherapy 
response primarily because it gave a numerical score which proved particularly 
convenient when it came to the cross-over study between the two pathologists. Its 
principal shortcoming is the lack of comparison with the baseline core biopsy but from 
a clinical point of view the tumour burden following chemotherapy is a sensible feature 
to measure and has been shown to correlate well with outcomes at 10 years follow 
up.16  One of the important aspects of ARTemis is the future programme of 
translational research and that has required sections from core biopsies, excised 
tumours and nodes to be marked up for future tissue sampling. A pathologist would 
certainly be required to support that aspect of a future trial. The central review process 
described here also provides great confidence in the recorded ARTemis endpoints, 
thus supporting subsequent translational work aimed at understanding the 
determinants of individual tumour response and the correlations of that with long term 
outcomes. Recently it has been shown that combining residual cancer burden with 
Ki67 measurements further increases the predictive power of this tool. 17  Also there 
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is a growing interest in either post-neo-adjuvant studies, or allowing patients to enter 
other studies post-neoadjuvant chemotherapy which means that where low volumes 
of residual disease are permitted in such studies, perhaps caution is needed about 
relying on local reporting – whereas for pathological complete response or bulk 
residual disease one can rely on local reporting.
  
CONCLUSION 
Central pathology review of the ARTemis trial has allowed a direct comparison with 
report-review and has shown that when the primary end point of the trial pathological 
complete response, is compared, the two methods are equally effective. Central 
pathology review has a place in the assessment of minimal residual disease but if that 
is not an agreed pre-specified trial end point there is little extra value in doing this. 
Learning from the experience of ARTemis, future neoadjuvant clinical trials could be 
improved by training in the routine calculation of residual cancer burden. Also, 
standardised routine reporting using report templates would greatly assist in report-
review.18 Such training might provide more robust reporting of residual cancer burden 
classes, facilitating future clinical management, when current and planned trials of 
adjuvant treatment in patients not achieving a pathological complete response to 
neoadjuvant therapy come to fruition.  
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Legends for Tables and Figures 
 
 
Table 1: Patient characteristics 
 
Table 2: Residual cancer burden categories for the 65 patients, by the two 
pathologists 
 
Table 3: Levels of residual cancer at surgery, from the two assessment methods for 
the 781 patients 
Table 4A: Treatment arm comparison using local pathology report review data (n=781 
patients)  
Table 4B: Treatment arm comparison using central pathology specimen review data 
(n=587 patients) 
 
Figure 1: Level of agreement across two pathologists’ rating of residual cancer burden 
class: 
One rectangle is depicted for each level of residual cancer burden class, their height 
and width based on the row and column cumulative totals. Thus for the residual cancer 
burden 0 rectangle of pathologist 1 vs pathologist 2 comparison, all patient’s 
categorised as residual cancer burden 0 by either pathologist are included. The 
boundaries of the rectangles along both axes represent the number of patients that 
were categorised as residual cancer burden 0 for each pathologist. Dark squares 
within the rectangles represent exact agreement between residual cancer burden 
classes from the two pathologists (i.e. both rating as residual cancer burden 0), and 
are of size based on the cell frequencies and located according to the cumulative totals 
of the previous levels. Light rectangles represent partial agreement, where the residual 
cancer burden class from one pathologist is 1 different of the residual cancer burden 
class from the other pathologist (i.e. residual cancer burden 0 by one pathologist but 
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residual cancer burden 1 by the other pathologist). White areas within the rectangle 
reflect disagreement by more than level (i.e. residual cancer burden 0 by one 
pathologist and residual cancer burden 2 or 3 by the other pathologist). 
Figures 2A and 2B: Inter-rater reliability of pathologists’ residual cancer burden scores, 
where there is disagreement in residual cancer burden class (n=13 patients) 
2A – Pathologist 1 v Pathologist 2 residual cancer burden scores 
2B – Average of the two pathologist’s residual cancer burden scores 
Figure 3: Level of agreement across the two methods of review: 
One rectangle is depicted for each level of pathologic response, their height and width 
based on the row and column cumulative totals. Thus for the residual cancer burden 
0/pathCR rectangle of method comparison, all patient’s categorised as residual cancer 
burden 0 by pathologist or pathological complete response by report review are 
included. The boundaries of the rectangles along both axes represent the number of 
patients that were categorised as residual cancer burden 0/pathological complete 
response. Dark squares within the rectangles represent exact agreement between 
methods (i.e. pathologist rating as residual cancer burden 0 and report review as 
pathological complete response), and are of size based on the cell frequencies and 
located according to the cumulative totals of the previous levels. Light rectangles 
represent partial agreement, where the conclusion from the pathologist is 1 group 
different to that from the report review (i.e. residual cancer burden 0 by pathologist but 
minimal residual disease by report review). White areas within the rectangle reflect 
disagreement by more than level (i.e. residual cancer burden 0 by pathologist and 
Moderate/extensive residual disease by report review). 
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